In that perspective the decreased expression level of HLX1 in circulating CD4+ T-cells from IFN-β treated MS patients is difficult to explain and may be related to the wide range of molecules and pathways type-I IFNs interfere with. Here, CD4 is linked to myeloid sarcoma.